DOCS vs. JNJ: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DOCS and JNJ, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | DOCS | JNJ |
|---|---|---|
| Company Name | Doximity, Inc. | Johnson & Johnson |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Technology | Pharmaceuticals |
| Market Capitalization | 9.17 billion USD | 479.10 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 24, 2021 | January 2, 1962 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of DOCS and JNJ by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DOCS | JNJ |
|---|---|---|
| 5-Day Price Return | -5.56% | 3.99% |
| 13-Week Price Return | -23.81% | 10.92% |
| 26-Week Price Return | -17.89% | 31.99% |
| 52-Week Price Return | -6.13% | 27.86% |
| Month-to-Date Return | -24.82% | 3.74% |
| Year-to-Date Return | -7.06% | 35.48% |
| 10-Day Avg. Volume | 2.51M | 7.26M |
| 3-Month Avg. Volume | 1.57M | 8.51M |
| 3-Month Volatility | 42.88% | 13.39% |
| Beta | 1.42 | 0.33 |
Profitability
Return on Equity (TTM)
DOCS
23.90%
Health Care Technology Industry
- Max
- 48.09%
- Q3
- 42.04%
- Median
- 18.65%
- Q1
- 11.64%
- Min
- 11.05%
DOCS’s Return on Equity of 23.90% is on par with the norm for the Health Care Technology industry, indicating its profitability relative to shareholder equity is typical for the sector.
JNJ
32.69%
Pharmaceuticals Industry
- Max
- 38.95%
- Q3
- 20.34%
- Median
- 11.59%
- Q1
- 3.32%
- Min
- -10.91%
In the upper quartile for the Pharmaceuticals industry, JNJ’s Return on Equity of 32.69% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
DOCS
40.72%
Health Care Technology Industry
- Max
- 52.24%
- Q3
- 49.36%
- Median
- 34.00%
- Q1
- 16.86%
- Min
- 13.38%
DOCS’s Net Profit Margin of 40.72% is aligned with the median group of its peers in the Health Care Technology industry. This indicates its ability to convert revenue into profit is typical for the sector.
JNJ
27.26%
Pharmaceuticals Industry
- Max
- 39.07%
- Q3
- 19.28%
- Median
- 13.48%
- Q1
- 5.73%
- Min
- -8.86%
A Net Profit Margin of 27.26% places JNJ in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
DOCS
39.72%
Health Care Technology Industry
- Max
- 74.05%
- Q3
- 65.47%
- Median
- 33.33%
- Q1
- 22.83%
- Min
- 21.46%
DOCS’s Operating Profit Margin of 39.72% is around the midpoint for the Health Care Technology industry, indicating that its efficiency in managing core business operations is typical for the sector.
JNJ
34.19%
Pharmaceuticals Industry
- Max
- 45.58%
- Q3
- 24.35%
- Median
- 18.05%
- Q1
- 7.58%
- Min
- -11.88%
An Operating Profit Margin of 34.19% places JNJ in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | DOCS | JNJ |
|---|---|---|
| Return on Equity (TTM) | 23.90% | 32.69% |
| Return on Assets (TTM) | 20.66% | 13.22% |
| Net Profit Margin (TTM) | 40.72% | 27.26% |
| Operating Profit Margin (TTM) | 39.72% | 34.19% |
| Gross Profit Margin (TTM) | 90.20% | 68.14% |
Financial Strength
Current Ratio (MRQ)
DOCS
7.79
Health Care Technology Industry
- Max
- 7.79
- Q3
- 6.49
- Median
- 6.03
- Q1
- 3.62
- Min
- 2.96
DOCS’s Current Ratio of 7.79 is in the upper quartile for the Health Care Technology industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
JNJ
1.07
Pharmaceuticals Industry
- Max
- 5.45
- Q3
- 2.99
- Median
- 1.98
- Q1
- 1.29
- Min
- 0.78
JNJ’s Current Ratio of 1.07 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
DOCS
0.00
Health Care Technology Industry
- Max
- 0.14
- Q3
- 0.10
- Median
- 0.01
- Q1
- 0.00
- Min
- 0.00
Falling into the lower quartile for the Health Care Technology industry, DOCS’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
JNJ
0.58
Pharmaceuticals Industry
- Max
- 1.79
- Q3
- 0.78
- Median
- 0.31
- Q1
- 0.08
- Min
- 0.00
JNJ’s Debt-to-Equity Ratio of 0.58 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
DOCS
--
Health Care Technology Industry
- Max
- 224.12
- Q3
- 224.12
- Median
- 219.00
- Q1
- 219.00
- Min
- 219.00
Interest Coverage Ratio data for DOCS is currently unavailable.
JNJ
34.01
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 10.15
- Q1
- 2.37
- Min
- -42.71
JNJ’s Interest Coverage Ratio of 34.01 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | DOCS | JNJ |
|---|---|---|
| Current Ratio (MRQ) | 7.79 | 1.07 |
| Quick Ratio (MRQ) | 7.26 | 0.71 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.58 |
| Interest Coverage Ratio (TTM) | -- | 34.01 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DOCS
0.00%
Health Care Technology Industry
- Max
- 0.77%
- Q3
- 0.62%
- Median
- 0.19%
- Q1
- 0.05%
- Min
- 0.00%
DOCS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
JNJ
2.55%
Pharmaceuticals Industry
- Max
- 6.72%
- Q3
- 3.48%
- Median
- 1.90%
- Q1
- 0.00%
- Min
- 0.00%
JNJ’s Dividend Yield of 2.55% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
DOCS
0.00%
Health Care Technology Industry
- Max
- 101.92%
- Q3
- 87.10%
- Median
- 42.63%
- Q1
- 10.66%
- Min
- 0.00%
DOCS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
JNJ
48.70%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 85.87%
- Median
- 49.36%
- Q1
- 1.12%
- Min
- 0.00%
JNJ’s Dividend Payout Ratio of 48.70% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | DOCS | JNJ |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.55% |
| Dividend Payout Ratio (TTM) | 0.00% | 48.70% |
Valuation
Price-to-Earnings Ratio (TTM)
DOCS
35.02
Health Care Technology Industry
- Max
- 225.71
- Q3
- 183.85
- Median
- 51.77
- Q1
- 45.26
- Min
- 35.02
In the lower quartile for the Health Care Technology industry, DOCS’s P/E Ratio of 35.02 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
JNJ
19.12
Pharmaceuticals Industry
- Max
- 52.64
- Q3
- 29.89
- Median
- 20.77
- Q1
- 13.37
- Min
- 5.71
JNJ’s P/E Ratio of 19.12 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
DOCS
14.26
Health Care Technology Industry
- Max
- 117.92
- Q3
- 92.41
- Median
- 15.08
- Q1
- 8.11
- Min
- 6.06
DOCS’s P/S Ratio of 14.26 aligns with the market consensus for the Health Care Technology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
JNJ
5.21
Pharmaceuticals Industry
- Max
- 8.74
- Q3
- 4.66
- Median
- 2.37
- Q1
- 1.67
- Min
- 0.11
JNJ’s P/S Ratio of 5.21 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
DOCS
12.51
Health Care Technology Industry
- Max
- 115.01
- Q3
- 89.39
- Median
- 9.75
- Q1
- 4.04
- Min
- 3.06
DOCS’s P/B Ratio of 12.51 is within the conventional range for the Health Care Technology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
JNJ
5.52
Pharmaceuticals Industry
- Max
- 9.86
- Q3
- 5.28
- Median
- 2.48
- Q1
- 1.57
- Min
- 0.59
JNJ’s P/B Ratio of 5.52 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | DOCS | JNJ |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 35.02 | 19.12 |
| Price-to-Sales Ratio (TTM) | 14.26 | 5.21 |
| Price-to-Book Ratio (MRQ) | 12.51 | 5.52 |
| Price-to-Free Cash Flow Ratio (TTM) | 28.39 | 24.51 |